LSA
PPH icon

L & S Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

L & S Advisors’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,869
Closed -$273K – 365
2024
Q3 		$273K Sell
2,869
-80
-3% -$7.6K 0.03% 296
2024
Q2 		$270K Sell
2,949
-5
-0.2% -$446 0.03% 275
2024
Q1 		$268K Buy
+2,954
New +$259K 0.03% 283

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

L & S Advisors's PPH Position: Q4 2024 in Review

L & S Advisors sold out of VanEck Pharmaceutical ETF (PPH) in Q4 2024, closing a stake of 2,869 shares — an estimated $273K sold.

L & S Advisors first reported a position in PPH in Q1 2024 and held it in 3 quarters. The position peaked at $273K in Q3 2024. 142 funds tracked by Wall St. Rank hold PPH as of Q4 2024.

  • L & S Advisors reported no remaining VanEck Pharmaceutical ETF position as of Q4 2024 after selling out during the quarter.
  • L & S Advisors sold 2,869 VanEck Pharmaceutical ETF shares in Q4 2024, an estimated $273K.
  • L & S Advisors first reported a position in VanEck Pharmaceutical ETF in Q1 2024 and held it in 3 quarters.
  • L & S Advisors's VanEck Pharmaceutical ETF position peaked at $273K in Q3 2024.
  • 142 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2024.

Based on L & S Advisors's 13F filing for Q4 2024, filed 12 Feb 2025.